These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39298261)

  • 41. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China.
    Yang P; Dang B; Kang W; Li X; Wang T; Li R; Peng M; Liu Y; Wang L; Cheng Y; Yu S; Wei M; Gao H; Kang W; Shang L
    Front Public Health; 2023; 11():1107343. PubMed ID: 36960364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021.
    Ravindran S; Gubbay JB; Cronin K; Sullivan A; Zygmunt A; Johnson K; Buchan SA; Parpia AS
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad282. PubMed ID: 37274182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
    Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
    Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Likelihood of infecting or getting infected with COVID-19 as a function of vaccination status, as investigated with a stochastic model for Aotearoa New Zealand for Delta and Omicron variants.
    Watson LM
    N Z Med J; 2022 Apr; 135():89-100. PubMed ID: 35728188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens - San Francisco Bay Area, California, July 2021-March 2022.
    Tassetto M; Garcia-Knight M; Anglin K; Lu S; Zhang A; Romero M; Pineda-Ramirez J; Sanchez RD; Donohue KC; Pfister K; Chan C; Saydah S; Briggs-Hagen M; Peluso MJ; Martin JN; Andino R; Midgley CM; Kelly JD
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(36):1151-1154. PubMed ID: 36074732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
    Matsumoto N; Sasaki A; Kadowaki T; Mitsuhashi T; Takao S; Yorifuji T
    Vaccine; 2024 Aug; 42(21):126156. PubMed ID: 39088986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
    Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
    JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The "vaccine" hubbub: Viral load comparisons of SARS-CoV-2 Delta and Omicron variants against different vaccine-booster vaccine combinations.
    Ergoren MC; Akan G; Volkan E; Kandemis E; Evren EU; Evren H; Volkan E; Tuncel G; Suer K; Sanlidag T
    J Med Virol; 2023 Jan; 95(1):e28309. PubMed ID: 36377303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
    Eyre DW; Futschik M; Tunkel S; Wei J; Cole-Hamilton J; Saquib R; Germanacos N; Dodgson AR; Klapper PE; Sudhanva M; Kenny C; Marks P; Blandford E; Hopkins S; Peto TEA; Fowler T
    Lancet Infect Dis; 2023 Aug; 23(8):922-932. PubMed ID: 37001541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients.
    Ong DSY; de Man P; Verhagen T; Doejaaren G; Dallinga MA; Alibux E; Janssen ML; Wils EJ
    J Med Virol; 2023 Apr; 95(4):e28748. PubMed ID: 37185846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 rapid antigen test sensitivity and viral load in newly symptomatic hospital employees in Berlin, Germany, December, 2020 to February, 2022: an observational study.
    Meiners L; Horn J; Jones TC; Mühlemann B; Schmidt ML; Walper F; Menzel P; Schwarzer R; Rose R; Krumbholz A; Corman VM; Seybold J; Drosten C
    Lancet Microbe; 2024 Jun; 5(6):e538-e546. PubMed ID: 38759669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.